MAM
CDTX

Meeder Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Meeder Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-225
Closed -$17K – 2344
2019
Q4 		$17K Hold
225
– – ﹤0.01% 1405
2019
Q3 		$9K Sell
225
-30
-12% -$1.01K ﹤0.01% 1562
2019
Q2 		$9K Buy
255
+110
+76% +$4.57K ﹤0.01% 1480
2019
Q1 		$8K Hold
145
– – ﹤0.01% 1294
2018
Q4 		$7K Buy
145
+19
+15% +$1.36K ﹤0.01% 1328
2018
Q3 		$11K Buy
126
+72
+133% +$6.35K ﹤0.01% 1137
2018
Q2 		$5.65K Buy
54
+16
+42% +$1.51K ﹤0.01% 1246
2018
Q1 		$3K Buy
38
+4
+12% +$546 ﹤0.01% 1316
2017
Q4 		$5K Sell
34
-16
-32% -$2.43K ﹤0.01% 1303
2017
Q3 		$8K Buy
50
+33
+194% +$4.69K ﹤0.01% 1122
2017
Q2 		$3K Sell
17
-14
-45% -$1.94K ﹤0.01% 1315
2017
Q1 		$5K Sell
31
-58
-65% -$10.2K ﹤0.01% 1056
2016
Q4 		$19K Buy
+89
New +$18.5K ﹤0.01% 662

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Meeder Asset Management's CDTX Position: Q1 2020 in Review

Meeder Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2020, closing a stake of 225 shares — an estimated $17K sold.

Meeder Asset Management first reported a position in CDTX in Q4 2016 and held it in 13 quarters. The position peaked at $19K in Q4 2016. 53 funds tracked by Wall St. Rank hold CDTX as of Q1 2020.

  • Meeder Asset Management reported no remaining Cidara Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Meeder Asset Management sold 225 Cidara Therapeutics shares in Q1 2020, an estimated $17K.
  • Meeder Asset Management first reported a position in Cidara Therapeutics in Q4 2016 and held it in 13 quarters.
  • Meeder Asset Management's Cidara Therapeutics position peaked at $19K in Q4 2016.
  • 53 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.